Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs. Novo Nordisk A/S, Mike Doustdar, GLP-1 RAs (Drug), Ozempic (Drug), Denmark, Durham (NC), United States, Drugs (Pharmaceuticals), Weight, vis-photo Read More
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
